RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaN/A

Registered title, quoted from ClinicalTrials.gov

Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07537959, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Hepatocellular carcinoma confirmed by imaging and/or histology according to AASLD or EASL criteria

    Inclusion criterion 2

  3. Child-Pugh class A or stable Child-Pugh B7

    Inclusion criterion 6

  4. ECOG performance status 0 to 1

    Inclusion criterion 4

  5. At least one measurable extrahepatic metastatic lesion according to RECIST version 1.1

    Inclusion criterion 5

  6. Pregnancy or breastfeeding

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07537959, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18 to 75 years
  • Hepatocellular carcinoma confirmed by imaging and/or histology according to AASLD or EASL criteria
  • Resectable primary intrahepatic tumor with expected R0 resection
  • ECOG performance status 0 to 1
  • At least one measurable extrahepatic metastatic lesion according to RECIST version 1.1
  • Child-Pugh class A or stable Child-Pugh B7
  • Written informed consent and willingness to comply with study follow-up and data collection

Exclusion Criteria:

  • Prior systemic therapy for hepatocellular carcinoma, including immunotherapy, targeted therapy, or chemotherapy
  • Decompensated or clinically unstable liver disease, including refractory ascites, recurrent hepatic encephalopathy, active gastrointestinal bleeding, or - Child-Pugh class greater than B7
  • Major bleeding risk or clinically significant coagulation abnormality, including recent gastrointestinal bleeding or untreated/high-risk gastroesophageal varices
  • Active autoimmune disease or long-term systemic immunosuppressive therapy
  • Active severe infection, including uncontrolled bacterial or fungal infection, uncontrolled hepatitis B virus replication without appropriate antiviral treatment, or active tuberculosis
  • Uncontrolled central nervous system metastases
  • Uncontrolled cardiovascular disease, including poorly controlled hypertension, recent myocardial infarction, unstable angina, stroke, or major thrombotic event
  • Significant proteinuria or renal dysfunction considered unsuitable for study treatment
  • Another active malignancy, except for selected low-risk malignancies allowed by the investigator and ethics committee
  • Pregnancy or breastfeeding
  • Known severe hypersensitivity to study-related drugs
  • Poor compliance, psychiatric or cognitive disorder preventing study participation, or any other condition judged by the investigator to make the participant unsuitable for the trial

Quoted from ClinicalTrials.gov, NCT07537959, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07537959, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07537959